NCT05526144View on ClinicalTrials.gov

Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

PHASE2RecruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions
Nonalcoholic SteatohepatitisLiver Fibrosis
Interventions
DRUG

Synthroid

Synthroid tablets 25 mcg. Subjects in the study group will receive Synthroid at a titrated dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for one year duration that will maintain TSH at normal level.

DRUG

Placebo

Placebo tablets 25 mcg daily. Subjects in the placebo group will receive placebo tablets at a dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for a one year duration.

Trial Locations (1)

65201-5275

RECRUITING

Harry S. Truman Memorial, Columbia, MO, Columbia

All Listed Sponsors
lead

VA Office of Research and Development

FED